158 related articles for article (PubMed ID: 31674877)
1. Proportion of cores with the highest Gleason grade group among positive cores on prostate biopsy: does this affect the probability of upgrading or downgrading?
Yoo S; Suh J; Park J; Cho MC; Son H; Jeong H
Scand J Urol; 2019 Dec; 53(6):372-377. PubMed ID: 31674877
[No Abstract] [Full Text] [Related]
2. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
King CR; McNeal JE; Gill H; Presti JC
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152
[TBL] [Abstract][Full Text] [Related]
3. Combined multiple clinical characteristics for prediction of discordance in grade and stage in prostate cancer patients undergoing systematic biopsy and radical prostatectomy.
Liu H; Tang K; Xia D; Peng E; Wang L; Chen Z
Pathol Res Pract; 2020 Nov; 216(11):153235. PubMed ID: 33035728
[TBL] [Abstract][Full Text] [Related]
4. Postoperative upgrading of prostate cancer in men ≥75 years: a propensity score-matched analysis.
Herlemann A; Buchner A; Kretschmer A; Apfelbeck M; Stief CG; Gratzke C; Tritschler S
World J Urol; 2017 Oct; 35(10):1517-1524. PubMed ID: 28493044
[TBL] [Abstract][Full Text] [Related]
5. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
6. Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications.
Freedland SJ; Kane CJ; Amling CL; Aronson WJ; Terris MK; Presti JC;
Urology; 2007 Mar; 69(3):495-9. PubMed ID: 17382152
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (> or = 12)-core prostate biopsy.
Hong SK; Han BK; Lee ST; Kim SS; Min KE; Jeong SJ; Jeong H; Byun SS; Lee HJ; Choe G; Lee SE
World J Urol; 2009 Apr; 27(2):271-6. PubMed ID: 19020885
[TBL] [Abstract][Full Text] [Related]
8. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms.
Gancarczyk KJ; Wu H; McLeod DG; Kane C; Kusuda L; Lance R; Herring J; Foley J; Baldwin D; Bishoff JT; Soderdahl D; Moul JW
Urology; 2003 Mar; 61(3):589-95. PubMed ID: 12639653
[TBL] [Abstract][Full Text] [Related]
9. Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer.
Ranasinghe W; Reichard CA; Nyame YA; Sundi D; Tosoian JJ; Wilkins L; Alam R; Achim MF; Wang X; Stephenson AJ; Klein EA; Ross AE; Allaf ME; Davis JW; Chapin BF
J Urol; 2020 Oct; 204(4):748-753. PubMed ID: 32259468
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
[TBL] [Abstract][Full Text] [Related]
11. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
[TBL] [Abstract][Full Text] [Related]
12. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
Caster JM; Falchook AD; Hendrix LH; Chen RC
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of MRI-Targeted in-Bore Prostate Biopsy According to the Gleason Score with Postprostatectomy Histopathologic Control--a Targeted Biopsy-Only Strategy with Limited Number of Cores.
Garmer M; Busch M; Mateiescu S; Fahlbusch DE; Wagener B; Grönemeyer DH
Acad Radiol; 2015 Nov; 22(11):1409-18. PubMed ID: 26343218
[TBL] [Abstract][Full Text] [Related]
14. The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy.
Arsov C; Becker N; Rabenalt R; Hiester A; Quentin M; Dietzel F; Antoch G; Gabbert HE; Albers P; Schimmöller L
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2061-8. PubMed ID: 26013424
[TBL] [Abstract][Full Text] [Related]
15. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
16. Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer.
Krane LS; Menon M; Kaul SA; Siddiqui SA; Wambi C; Peabody JO; Agarwal PK
Urol Oncol; 2011; 29(4):372-7. PubMed ID: 19576796
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of "regression to the mean" using routine clinical features with correlating biochemical relapse rates.
Altok M; Troncoso P; Achim MF; Matin SF; Gonzalez GN; Davis JW
Asian J Androl; 2019; 21(6):598-604. PubMed ID: 31115364
[TBL] [Abstract][Full Text] [Related]
18. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
Yang DD; Mahal BA; Muralidhar V; Nezolosky MD; Vastola ME; Labe SA; Boldbaatar N; King MT; Martin NE; Orio PF; Beard CJ; Hoffman KE; Trinh QD; Spratt DE; Feng FY; Nguyen PL
Eur Urol Focus; 2019 Jan; 5(1):69-76. PubMed ID: 28753811
[TBL] [Abstract][Full Text] [Related]
19. Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer.
Preisser F; Würnschimmel C; Pose RM; Heinze A; Steuber T; Michl U; Salomon G; Mandel P; Graefen M; Tilki D
Prostate; 2022 Feb; 82(2):254-259. PubMed ID: 34807461
[TBL] [Abstract][Full Text] [Related]
20. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
